Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Life Science

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0024-3205(91)90526-HPMID 1900558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of opiate antagonists and putative κ agonists on unpunished and punished operant behavior in the rat

  2004cited by this paper
• Antiparkinsonian effects of caffeine depend upon pavlovian drug conditioning processes.

  1990cited by this paper
• Dopamine receptors mediate drug-induced but not Pavlovian conditioned contralateral rotation in the unilateral 6-OHDA animal model.

  1990cited by this paper
• Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of μ and δ opioid receptors

  1989cited by this paper
• Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity.

  1989cited by this paper
• Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of mu and delta opioid receptors.

  1989cited by this paper
• Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

  1988cited by this paper
• Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area.

  1987cited by this paper
• Video image analysis of behavior by microcomputer: categorization of turning and locomotion after 6-OHDA injection into the substantia nigra.

  1987cited by this paper
• Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning.

  1987cited by this paper
• Opiate actions on mesocortical dopamine metabolism in the rat.

  1986cited by this paper
• Opioid binding sites in the nigrostriatal system of the guinea pig are not located on nigral dopaminergic neurons.

  1986cited by this paper
• Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.

  1986cited by this paper
• Place-conditioning properties of mu, kappa, and sigma opioid agonists.

  1985cited by this paper
• Naloxone may be beneficial in the treatment of tardive dyskinesia.

  1984cited by this paper
• Simultaneous multiple electrode liquid chromatographic-electrochemical assay for catecholamines, indole-amines and metabolites in brain tissue.

  1983cited by this paper
• Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.

  1980cited by this paper
• Circling behavior and stereotypy induced by intranigral opiate microinjections.

  1977cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper

• Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

  2019cites this paper
• Effects of Opioid Antagonists on l-DOPA-Induced Dyskinesia in Parkinson's Disease

  2009cites this paper
• Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease

  2008cites this paper
• Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic Rats

  2005cites this paper
• Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.

  2004cites this paper
• Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.

  2003cites this paper
• Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinson’s disease

  2002cites this paper
• Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

  2002influential citation
• Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism

  2002cites this paper
• Address for correspondence

  2001cites this paper
• Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine.

  2001cites this paper
• Non-dopaminergic drug treatment of Parkinson’s disease

  2001cites this paper
• Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

  1999cites this paper
• Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP

  1999cites this paper
• Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

  1999cites this paper
• [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].

  1999cites this paper
• Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat.

  1998cites this paper
• Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  1998cites this paper
• Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys.

  1998cites this paper
• L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA

  1998cites this paper
• Alterations in opioid receptor binding in Parkinson's disease patients with levodopa‐induced dyskinesias

  1997cites this paper
• Potential of Opioid Antagonists in the Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease

  1996cites this paper
• Densitometrical analysis of opioid receptor ligand binding in the human striatum--I. Distribution of mu opioid receptor defines shell and core of the ventral striatum.

  1996cites this paper
• Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.

  1995cites this paper
• Biological Models in Radiopharmaceutical Development

  1995cites this paper
• Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.

  1995cites this paper
• Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeys

  1995cites this paper
• The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.

  1994cites this paper
• Motoric Sensitization and Levodopa Accumulation After Chronic Levodopa Treatment in an Animal Model of Parkinson's Disease

  1993cites this paper
• The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia

  1993cites this paper
• Opioid receptor antagonists discriminate between presynaptic mu and delta receptors and the adenylate cyclase-coupled opioid receptor complex in the brain.

  1992cites this paper
• Endogenous opiates: 1991.

  1992cites this paper
• Beta-phenylethylamines and the isoquinoline alkaloids.

  1992cites this paper
• Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.

  1991cites this paper